Genetic Risk Score Predicts Late-Life Cognitive Impairment

Journal of Aging Research

Volumn 2015, Issue , 2015, Pages

  Wollam, Mariegold E ^a   Weinstein, Andrea M ^a,b   Saxton, Judith A ^a   Morrow, Lisa ^a   Snitz, Beth ^a   Fowler, Nicole R ^c   Suever Erickson, Barbara L ^a   Roecklein, Kathryn A ^a,b   Erickson, Kirk I ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE;

AGED; APOE GENE; ARTICLE; BDNF GENE; COGNITION; COGNITIVE DEFECT; COMT GENE; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; GENETIC RISK; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84941138987     PISSN: 20902204     EISSN: 20902212     Source Type: Journal    
DOI: 10.1155/2015/267062     Document Type: Article

References (50)

1. Alzheimer's Association, "2014 Alzheimer's disease facts and figures," Alzheimer's & Dementia, vol. 10, no. 2, pp. e47-e92, 2014.
2. M. Gatz, C. A. Reynolds, L. Fratiglioni et al., "Role of genes and environments for explaining Alzheimer disease," Archives of General Psychiatry, vol. 63, no. 2, pp. 168-174, 2006.
3. K. D. Coon, A. J. Myers, D. W. Craig et al., "A high-density whole-genome association study reveals thatAPOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease," Journal of Clinical Psychiatry, vol. 68, no. 4, pp. 613-618, 2007.
4. R. E. Pitas, J. K. Boyles, S.H. Lee,D.Hui, and K. H. Weisgraber, "Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain," The Journal of Biological Chemistry, vol. 262, no. 29, pp. 14352-14360, 1987.
5. L. A. Farrer, L. A. Cupples, J. L. Haines et al., "Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium," The Journal of the American Medical Association, vol. 278, no. 16, pp. 1349-1356, 1997.
6. D. C. Whitehair, A. Sherzai, J. Emond et al., "Influence of apolipoprotein e ε4 on rates of cognitive and functional decline in mild cognitive impairment," Alzheimer's and Dementia, vol. 6, no. 5, pp. 412-419, 2010.
7. S. Cosentino, N. Scarmeas, E. Helzner et al., "APOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease," Neurology, vol. 70, no. 19, pp. 1842-1849, 2008.
8. National Institutes of Health, National Institute on Aging, and Human Services Department, Alzheimer's Disease: Unraveling the Mystery, Government Printing Office, 2011.
9. D. K. Binder and H. E. Scharfman, "Brain-derived neurotrophic factor," Growth Factors, vol. 22, no. 3, pp. 123-131, 2004.
10. J. Lee, H. Fukumoto, J. Orne et al., "Decreased levels of BDNF protein inAlzheimer temporal cortex are independent ofBDNF polymorphisms," ExperimentalNeurology, vol. 194, no. 1,pp. 91-96, 2005.
11. M. Ventriglia, R. Zanardini, C. Bonomini et al., "Serum brainderived neurotrophic factor levels in different neurological diseases," BioMed Research International, vol. 2013, Article ID 901082, 7 pages, 2013.
12. K. I. Erickson, R. S. Prakash, M. W. Voss et al., "Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume," The Journal of Neuroscience, vol. 30, no. 15, pp. 5368-5375, 2010.
13. J. P. Kambeitz, S. Bhattacharyya, L. M. Kambeitz-Ilankovic, I. Valli, D. A. Collier, and P. McGuire, "Effect of BDNF val66met polymorphism on declarative memory and its neural substrate: a meta-analysis," Neuroscience and Biobehavioral Reviews, vol. 36, no. 9, pp. 2165-2177, 2012.
14. Y. Y. Lim, V. L. Villemagne, S.M. Laws et al., "BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease," Neurobiology of Aging, vol. 34, no. 11, pp. 2457-2464, 2013.
15. R. A. Honea, C. Cruchaga, R. D. Perea et al., "Characterizing the role of brain derived neurotrophic factor genetic variation in Alzheimer's disease neurodegeneration," PLoS ONE, vol. 8, no. 9, Article ID e76001, 2013.
16. L. Pezawas, B. A. Verchinski, V. S. Mattay et al., "The brainderived neurotrophic factor val66met polymorphism and variation in human cortical morphology," The Journal of Neuroscience, vol. 24, no. 45, pp. 10099-10102, 2004.
17. G. Laumet, V. Chouraki, B. Grenier-Boley et al., "Systematic analysis of candidate genes for Alzheimer's disease in a French, genome-wide association study," Journal of Alzheimer's Disease, vol. 20, no. 4, pp. 1181-1188, 2010.
18. R. Huang, J. Huang, H. Cathcart, S. Smith, and S. E. Poduslo, "Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease," Journal of Medical Genetics, vol. 44, no. 2, article e66, 2007.
19. Á. Fehér, A. Juhász, Á. Rimanóczy, J. Kálmán, and Z. Janka, "Association between BDNF Val66Met polymorphism and alzheimer disease, dementiawith lewy bodies, and pick disease," Alzheimer Disease and Associated Disorders, vol. 23, no. 3, pp. 224-228, 2009.
20. B. Bertocci, V.Miggiano, M.Da Prada, Z.Dembic, H.-W. Lahm, and P. Malherbe, "Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form," Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 4, pp. 1416-1420, 1991.
21. P. T.Männistö and S. Kaakkola, "Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors," Pharmacological Reviews, vol. 51, no. 4, pp. 593-628, 1999.
22. R. M. Bilder, J. Volavka, H. M. Lachman, and A. A. Grace, "The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes," Neuropsychopharmacology, vol. 29, no. 11, pp. 1943-1961, 2004.
23. J. H. Barnett, L. Scoriels, and M. R. Munafò, "Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism," Biological Psychiatry, vol. 64, no. 2, pp. 137-144, 2008.
24. G. E. Bruder, J. G. Keilp, H. Xu et al., "Catechol-Omethyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations," Biological Psychiatry, vol. 58, no. 11, pp. 901-907, 2005.
25. C. M. de Frias, K. Annerbrink, L. Westberg, E. Eriksson, R. Adolfsson, and L.-G. Nilsson, "COMT gene polymorphism is associated with declarative memory in adulthood and old age," Behavior Genetics, vol. 34, no. 5, pp. 533-539, 2004.
26. J. M. Starr, H. Fox, S. E. Harris, I. J. Deary, and L. J. Whalley, "COMT genotype and cognitive ability: a longitudinal aging study," Neuroscience Letters, vol. 421, no. 1, pp. 57-61, 2007.
27. E. Rodríguez-Rodríguez, P. Sánchez-Juan, J. L. Vázquez-Higuera et al., "Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease," Journal of Neural Transmission, vol. 120, no. 5, pp. 807-812, 2013.
28. L. G. Fritsche, W. Chen, M. Schu et al., "Seven new loci associated with age-related macular degeneration," Nature Genetics, vol. 45, no. 4, pp. 433-439, 2013.
29. P. L. De Jager, L. B. Chibnik, J. Cui et al., "Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score," The Lancet Neurology, vol. 8, no. 12, pp. 1111-1119, 2009.
30. M. C. Cornelis, L. Qi, C. Zhang et al., "Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry," Annals of Internal Medicine, vol. 150, no. 8, pp. 541-550, 2009.
31. B.E. Snitz,L.A.Morrow, E. G. Rodriguez, K. A. Huber, andJ.A. Saxton, "Subjective memory complaints and concurrent memory performance in older patients of primary care providers," Journal of the International Neuropsychological Society, vol. 14, no. 6, pp. 1004-1013, 2008.
32. L. A. Morrow, B. E. Snitz, E. G. Rodriquez, K. A. Huber, and J. A. Saxton, "High medical co-morbidity and family history of dementia is associated with lower cognitive function in older patients," Family Practice, vol. 26, no. 5, pp. 339-343, 2009.
33. N. R. Fowler, L. A. Morrow, L. Tu et al., "Association between cognitive decline in older adults and use of primary care physician services in Pennsylvania," Journal of Primary Care & Community Health, vol. 3, no. 3, pp. 201-209, 2012.
34. J. C. Morris, A. Heyman, R. C. Mohs et al., "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease," Neurology, vol. 39, no. 9, pp. 1159-1165, 1989.
35. D. Wechsler, Wechsler Memory Scale - Revised,The Psychological Corporation, New York, NY, USA, 1987.
36. M.-S. Shin, S.-Y. Park, S.-R. Park, S.-H. Seol, and J. S. Kwon, "Clinical and empirical applications of the Rey-Osterrieth Complex Figure Test," Nature Protocols, vol. 1, no. 2, pp. 892-899, 2006.
37. D.Wechsler, Wechsler Adult Intelligence Scale - RevisedManual, The Psychological Corporation, New York, NY, USA, 1981.
38. O. Spreen and E. Strauss, A Compendium of Neuropsychological Tests, Oxford University Press, New York, NY, USA, 1998.
39. R. M. Reitan, "Validity of the trail-making tests as an indication of organic brain damage," Perceptual and Motor skills, no. 8, pp. 271-276, 1958.
40. E. Kaplan, H. Goodglass, and S. Weintraub, Boston Naming Test, LippincottWilliams&Wilkins, Philadelphia, Pa,USA, 2nd edition, 2001.
41. L. S. Radloff, "The CES-D Scale: a self-report depression scale for research in the general population," Applied Psychological Measurement, vol. 1, no. 3, pp. 385-401, 1977.
42. I.McDowell andC.Newell,MeasuringHealth:AGuide to Rating Scales andQuestionnaires,OxfordUniversityPress,Oxford,UK, 1987.
43. D. Galasko, D. Bennett, M. Sano et al., "An inventory to assess activities of daily living for clinical trials in Alzheimer's disease," Alzheimer Disease&Associated Disorders, vol. 11, no. 2, pp. S33-S39, 1997.
44. M. Ganguli, J. Gilby, E. Seaberg, and S. Belle, "Depressive symptoms and associated factors in a rural elderly population: the MoVIES project," The American Journal of Geriatric Psychiatry, vol. 3, no. 2, pp. 144-160, 1995.
45. O. L. Lopez, J. T. Becker, W. Klunk et al., "Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II," Neurology, vol. 55, no. 12, pp. 1863-1869, 2000.
46. N. Fukumoto, T. Fujii,O. Combarros et al., "Sexually dimorphic effect of theVal66Met polymorphism ofBDNF on susceptibility to Alzheimer's disease: new data and meta-analysis," American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, vol. 153, no. 1, pp. 235-242, 2010.
47. J. S.Damoiseaux,W.W. Seeley, J.Zhouet al., "Gendermodulates the APOE epsilon4 effect in healthy older adults: convergent evidence fromfunctional brain connectivity and spinal fluid tau levels,"The Journal of Neuroscience, vol. 32, no. 24, pp. 8254-8262, 2012.
48. M. F. Martínez, X. E. Martín, L. G. Alcelay et al., "The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers," BMC Neuroscience, vol. 10, article 125, 2009.
49. K. Kauppi, L.-G. Nilsson, J. Persson, and L. Nyberg, "Additive genetic effect of APOE and BDNF on hippocampus activity," NeuroImage, vol. 89, pp. 306-313, 2014.
50. D. D. Ward, M. J. Summers, N. L. Saunders, P. Janssen, K. E. Stuart, and J. C. Vickers, "APOE and BDNF Val66Met polymorphisms combine to influence episodic memory function in older adults," Behavioural Brain Research, vol. 271, pp. 309-315, 2014.